Combination Therapy Shows Promise For Leptomeningeal Metastasis In Breast Cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have recovered a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend endurance in some breast cancer patients with LM. 

The Phase II study, published coming in Nature Cancer, included 17 female patients with newly diagnosed LM and HER2+ breast cancer. Median wide survival (OS) in those treated with the combination therapy increased from a historical average of 4.4 months to 10 months. At the 18-month mark, 41% of patients were still alive. Under the combination treatment, illness progression besides stalled, pinch a median of seven months before cardinal nervous system progression, and seven of 12 evaluable patients also had improved neurologic deficits. 

The operation achieved a clinically meaningful betterment successful wide endurance compared to humanities controls. For these patients, who often look constricted curen options, our results represent a step forward, offering caller dream successful really we dainty and manage leptomeningeal metastasis." 

Rashmi Murthy, M.D., lead author, subordinate professor of Breast Medical Oncology

Why are there constricted treatments for patients with leptomeningeal metastasis? 

Leptomeningeal metastasis is difficult to treat primarily because nan blood-brain obstruction whitethorn block drugs from reaching nan spinal fluid, where the metastatic cells are found. Additionally, LM is not a solid tumor but is made up of metastatic cells living successful fluid, making them more difficult to target. Historically, there also are few studies about this specific disease. 

"In summation to encouraging endurance outcomes, throughout this study we observed improvements successful neurologic symptoms," said co-lead author Barbara O'Brien, M.D., subordinate professor of Neuro-Oncology. "Treatments for bosom crab leptomeningeal metastasis person historically focused connected stabilizing illness alternatively than improving symptoms, making these findings peculiarly meaningful and encouraging." 

How do nan treatments in this combination therapy work? 

Tucatinib is a targeted therapy pill that blocks the HER2 protein, which helps immoderate breast cancers grow. Trastuzumab is simply a targeted antibody that attaches to nan HER2 macromolecule connected crab cells and helps nan immune strategy destruct them. Finally, capecitabine is simply a chemotherapy pill that turns into 5-fluorouracil (5-FU) successful nan body to eliminate fast-growing crab cells. 

The azygous arm, non-randomized, multi-phase study enrolled patients at 4 sites successful the U.S., including UT MD Anderson. Eligible patients were at least 18 years old with histologically proven metastatic HER2+ bosom carcinoma. These patients were treated pinch 21-day cycles of oral tucatinib (300 mg) doubly daily, positive oral capecitabine (1000 mg/m2) doubly regular on days 1-14 and intravenous trastuzumab (6 mg/kg) on day 21. 

What are other key findings of nan study? 

Side effects included diarrhea, nausea, vomiting, hand-foot syndrome, and liver usability trial elevation. Most adverse effects improved aliases resolved with appropriate care and dose modifications. One diligent saw alanine aminotransferase elevation aft 1 cycle, which led to discontinuation of nan combination, and symptoms resolved aft 1 month. 

Study limitations see early termination owed to slow accrual following Food & Drug Administration (FDA) approval of the combination therapy. Additionally, LM from HER2+ metastatic bosom cancer is rare, resulting successful constricted published data. As a result, nan study creation was informed by nan mini magnitude of disposable retrospective evidence.